In a significant move to fortify the UK’s Life Sciences sector and bolster pandemic preparedness, British multinational pharmaceutical and biotechnology giant AstraZeneca has unveiled plans to invest £650 million in the UK.
The pharmaceutical firm’s investment will boost the UK’s £108 billion Life Sciences sector which currently provides over 300,000 high skilled jobs across the UK.
The significant investment, announced this week, encompasses a range of initiatives aimed at advancing research, manufacturing, and innovation in the field of UK healthcare.
AstraZeneca’s foremost commitment involves injecting £450 million into its manufacturing facility in Speke, Liverpool, earmarked for the research, development, and production of vaccines. Notably, the new facility is set to achieve operational net zero status, with power supplied entirely from renewable energy sources. This strategic investment underscores AstraZeneca’s dedication to advancing public health protection and combating future health crises.
Furthermore, AstraZeneca’s collaboration with the UK Health Security Agency (UKHSA) is poised to elevate the nation’s resilience against global health threats. Through a partnership aimed at advancing vaccine science, leveraging technology from both AstraZeneca’s Speke site and the UKHSA’s Vaccine Development Evaluation Centre (VDEC) at Porton Down, the initiative seeks to pioneer breakthroughs in vaccine development and evaluation.
In addition to its manufacturing expansion in Liverpool, AstraZeneca is set to enhance its presence in Cambridge with a £200 million investment, employing around 1,000 people and will be adjacent to its £1.1 billion global R&D Discovery Centre (DISC), which already hosts 2,300 researchers and scientists. This move aligns with the company’s commitment to fostering innovation and research excellence within Europe’s largest life sciences cluster, further solidifying the UK’s position as a global leader in healthcare innovation.
Social Care Secretary Victoria Atkins lauded the investment for its potential to strengthen the country’s healthcare system and bolster pandemic preparedness. She said:
“The UK is a global leader in the research and development of life saving vaccines. Today’s announcement is testament to this country’s Life Science capabilities – and our continued commitment to pandemic preparedness and global health.
“As well as creating new highly-skilled jobs, this investment will help maintain the UK’s position at the forefront of tackling emerging diseases, and support our work to make our healthcare system faster, simpler and fairer.”
Chancellor Jeremy Hunt hailed AstraZeneca’s investment as a testament to the UK’s attractiveness as a destination for life sciences investment. He underscored the government’s commitment to fostering an environment conducive to innovation and economic growth, highlighting the UK’s competitive business tax regime and its role in driving investment and job creation.
Chancellor Jeremy Hunt said:
“To drive investment we’ve delivered one of the most competitive business tax regimes of any major economy, as part of our plan to help our key industries to grow. Our £108 billion Life Sciences sector provides over 300,000 high skilled jobs across the UK and is crucial for the country’s health, wealth and resilience.
“We are sticking to our plan to make the UK one of the best places in world to invest in developing and manufacturing new, innovative medicines – both protecting public health and growing our economy. AstraZeneca’s investment plans are a vote of confidence in the attractiveness of UK as a Life Sciences superpower and strengthen our resilience for future health emergencies.”
Echoing Jeremy Hunt’s sentiments, AstraZeneca CEO Sir Pascal Soriot emphasised the company’s confidence in the UK’s life sciences capabilities and its dedication to driving innovation and patient access.
AstraZeneca Chief Executive Officer, Sir Pascal Soriot, said:
“AstraZeneca’s planned investment would enhance the UK’s pandemic preparedness and demonstrates our ongoing confidence in UK life sciences. We will continue to support the UK in driving innovation and patient access, building on the strong foundations which have been put in place.
“This year marks 25 years since the merger of UK-based Zeneca Group and Swedish Astra AB. We are proud of our British roots and how far we have come over that time – we are now a truly global company that has transformed the lives of millions of patients throughout the world with a relentless focus on science and innovation.”
Dr Isabel Oliver, Chief Scientific Officer at UKHSA, said:
“This investment will bolster the development of the UK’s vaccine capabilities and life sciences sector – critical components of the country’s resilience to future health threats.
“UKHSA majors on researching and developing new ways to strengthen the country’s defences against all health hazards – including future pandemics – and works routinely with a range of commercial and academic partners. We are looking forward to working with AstraZeneca to collectively protect the population’s health.”
AstraZeneca is a British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
As the UK marks 25 years since the merger of Zeneca Group and Astra AB, AstraZeneca’s latest investment stands as a testament to the company’s enduring commitment to advancing healthcare and transforming patient outcomes worldwide. With a focus on sustainability, innovation, and collaboration, AstraZeneca’s investment sets the stage for continued progress in the UK’s Life Sciences sector, reaffirming its status as a global hub for scientific excellence and innovation.
Photo credit: MARTIN SELLARS. Copyright: MARTIN SELLARS.
